Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Sep 4;2(9):e1912014.
doi: 10.1001/jamanetworkopen.2019.12014.

Association of BCG Vaccination in Childhood With Subsequent Cancer Diagnoses: A 60-Year Follow-up of a Clinical Trial

Nicholas T Usher  1   2 , Suyoung Chang  3 , Robin S Howard  4 , Adriana Martinez  4 , Lee H Harrison  5 , Mathuram Santosham  6   7 , Naomi E Aronson  1
Affiliations

Association of BCG Vaccination in Childhood With Subsequent Cancer Diagnoses: A 60-Year Follow-up of a Clinical Trial

Nicholas T Usher et al. JAMA Netw Open. .

Abstract

Importance: The BCG vaccine is currently the only approved tuberculosis vaccine and is widely administered worldwide, usually during infancy. Previous studies found increased rates of lymphoma and leukemia in BCG-vaccinated populations.

Objective: To determine whether BCG vaccination was associated with cancer rates in a secondary analysis of a BCG vaccine trial.

Design, setting, and participants: Retrospective review (60-year follow-up) of a clinical trial in which participants were assigned to the vaccine group by systematic stratification by school district, age, and sex, then randomized by alternation. The original study was conducted at 9 sites in 5 US states between December 1935 and December 1998. Participants were 2963 American Indian and Alaska Native schoolchildren younger than 20 years with no evidence of previous tuberculosis infection. Statistical analysis was conducted between August 2018 and July 2019.

Interventions: Single intradermal injection of either BCG vaccine or saline placebo.

Main outcomes and measures: The primary outcome was diagnosis of cancer after BCG vaccination. Data on participant interval health and risk factors, including smoking, tuberculosis infection, isoniazid use, and other basic demographic information, were also collected.

Results: A total of 2963 participants, including 1540 in the BCG vaccine group and 1423 in the placebo group, remained after exclusions. Vaccination occurred at a median (interquartile range) age of 8 (5-11) years; 805 participants (52%) in the BCG group and 710 (50%) in the placebo group were female. At the time of follow-up, 97 participants (7%) in the placebo group and 106 participants (7%) in the BCG vaccine group could not be located; total mortality was 633 participants (44%) in the placebo group and 632 participants (41%) in the BCG group. The overall rate of cancer diagnosis was not significantly different in BCG vaccine vs placebo recipients (hazard ratio, 0.82; 95% CI, 0.66-1.02), including for lymphoma and leukemia. The rate of lung cancer was significantly lower in BCG vs placebo recipients (18.2 vs 45.4 cases per 100 000 person-years; hazard ratio, 0.38; 95% CI, 0.20-0.74; P = .005), controlling for sex, region, alcohol overuse, smoking, and tuberculosis.

Conclusions and relevance: Childhood BCG vaccination was associated with a lower risk of lung cancer development in American Indian and Alaska Native populations. This finding has potentially important health implications given the high mortality rate associated with lung cancer and the availability of low-cost BCG vaccines.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Harrison reported consulting with GlaxoSmithKline, Sanofi Pasteur, Pfizer, and Merck on epidemiology and vaccine prevention outside the submitted work. Dr Aronson reported receiving research funding from Walter Reed Army Medical Center and the Indian Health Service contract to Johns Hopkins University and grants from the Armed Forces Infectious Diseases Society during the conduct of the study; and at-cost vaccine supplies from the Japan BCG Laboratory and grants from the Defense Health Agency outside the submitted work. No other disclosures were reported.

Figures

Figure 1.
Figure 1.. Study Flow Diagram
Figure 2.
Figure 2.. Survival Analysis for Lung Cancer in BCG Vaccine and Placebo Groups
Cox regression for lung cancer development, controlling for sex, region, alcohol overuse, smoking, and tuberculosis status. All statistical testing performed using the Cox proportional hazards Wald test with 95% CI for variable significance. HR indicates hazard ratio.
See this image and copyright information in PMC

References

    1. World Health Organization Global health estimates. http://www.who.int/healthinfo/global_burden_disease/en/. Accessed May 6, 2019.
    1. Mangtani P, Abubakar I, Ariti C, et al. . Protection by BCG vaccine against tuberculosis: a systematic review of randomized controlled trials. Clin Infect Dis. 2014;58(4):-. doi:10.1093/cid/cit790 - DOI - PubMed
    1. Aronson NE, Santosham M, Comstock GW, et al. . Long-term efficacy of BCG vaccine in American Indians and Alaska Natives: a 60-year follow-up study. JAMA. 2004;291(17):2086-2091. doi:10.1001/jama.291.17.2086 - DOI - PubMed
    1. Pettenati C, Ingersoll MA. Mechanisms of BCG immunotherapy and its outlook for bladder cancer. Nat Rev Urol. 2018;15(10):615-625. doi:10.1038/s41585-018-0055-4 - DOI - PubMed
    1. de Bree LCJ, Koeken VACM, Joosten LAB, et al. . Non-specific effects of vaccines: current evidence and potential implications. Semin Immunol. 2018;39:35-43. doi:10.1016/j.smim.2018.06.002 - DOI - PubMed

Publication types